Highly cited cancer papers, 2008–2010
A N A LY S I S
highly cited cancer papers, 2008–2010The following tables show the primary research papers on cancer published between 2008 and 2010 that have had the highest number of citations in
the literature. To create these tables, we queried the Scopus
database) to search for articles that included the term ‘cancer’
or related terms in the title, abstract or keywords. After sorting the results on the basis of citation number, we removed reviews and epidemiological
studies. The predominance of genomic studies in these tables is remarkable. The number of citations is accurate as of 8 February 2010. The tables
include papers that have been cited at least 250 (2008 table), 125 (2009 table) and 35 (2010 table) times.
Highly cited cancer research published in 2008
Llovet, J.M. et al
. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359
Amado, R.G. et al.
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26
McLendon, R. et al.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455
Parsons, D.W. et al.
An integrated genomic analysis of human glioblastoma multiforme. Science 321
Mani, S.A. et al.
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133
Karapetis, C.S. et al.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359
Jones, S. et al.
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321
Lièvre, A. et al.
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetux-
imab. J. Clin. Oncol. 26
Scagliotti, G.V. et al.
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive
patients with advanced-stage non–small-cell lung cancer. J. Clin. Oncol. 26
Motzer, R.J. et al.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III
trial. Lancet 372
Saltz, L.B. et al.
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:
a randomized phase III study. J. Clin. Oncol. 26
Quintana, E. et al.
Efficient tumour formation by single human melanoma cells. Nature 456
Feng, H. et al.
Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 319
Gregory, P.A. et al.
The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat.
Cell Biol. 10
Tavazoie, S.F. et al.
Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451
Thorgeirsson, T.E. et al.
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452
Hung, R.J. et al.
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452
Amos, C.I. et al.
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 40
Mitchell, P.S. et al.
Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 105
Cunningham, D. et al.
Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med. 358
Di Nicolantonio, F. et al.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J. Clin.
Ben-Porath, I. et al.
An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors. Nat.
Ding, L. et al.
Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455
Qian, X. et al. In vivo
tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat. Biotech. 26
De Roock, W. et al.
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal can-
cer treated with cetuximab. Ann. Oncol. 19
Asangani, I.A. et al.
MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion,
intravasation and metastasis in colorectal cancer. Oncogene 27
volume 17 | number 3 | march 2011 NAture medIcINe
A N A LY S I S
Highly cited cancer research published in 2009
Schröder, F.H. et al.
Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360
Berg, C.D. et al.
Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360
Mok, T.S. et al.
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361
Van Cutsem, E. et al.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J.
Fong, P.C. et al.
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J.
Pàez-Ribes, M. et al.
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion
and distant metastasis. Cancer Cell 15
Lippman, S.M. et al.
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the selenium
and vitamin E cancer prevention trial (SELECT). J. Am. Med. Assoc. 301
Pirker, R. et al.
Cetuximab plus chemotherapy in patients with advanced non–small-cell lung cancer (FLEX): an
open-label randomised phase III trial. Lancet 373
Ebos, J.M. et al.
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Cancer Cell 15
Tol, J. et al.
Chemotherapy, bevacizumab and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360
Bokemeyer, C. et al.
Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment
of metastatic colorectal cancer. J. Clin. Oncol. 27
Reck, M. et al.
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy
for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 27
Gnant, M. et al.
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360
Yan, H. et al.
IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360
Cheng, A.-L. et al.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocel-
lular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10
Sreekumar, A. et al.
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.
Baxter, N.N. et al.
Association of colonoscopy and death from colorectal cancer. Ann. Internal Med. 150
Barker, N. et al.
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457
Stupp, R. et al.
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on
survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol.
Rosell, R. et al.
Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361
Hecht, J.R. et al.
A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with
chemotherapy and bevacizumab alone for metastatic colorectal cancer. J. Clin. Oncol. 27
Motzer, R.J. et al.
Overall survival and updated results for sunitinib compared with interferon a in patients with
metastatic renal cell carcinoma. J. Clin. Oncol. 27
Paavonen, J. et al.
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infec-
tion and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study
in young women. Lancet 374
Kota, J. et al.
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137
Irizarry, R.A. et al.
The human colon cancer methylome shows similar hypo- and hypermethylation at conserved
tissue-specific CpG island shores. Nat. Genet. 41
Grivennikov, S. et al.
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of
colitis-associated cancer. Cancer Cell 15
Sartore-Bianchi, A. et al.
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-
targeted monoclonal antibodies. Cancer Res. 69
Delhommeau, F. et al.
Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360
Gupta, P.B. et al.
Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138
Kim, S. et al.
Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 457
volume 17 | number 3 | march 2011
A N A LY S I S
Highly cited cancer research published in 2010
Pleasance, E.D. et al.
A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463
Pleasance, E.D. et al.
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463
Beroukhim, R. et al.
The landscape of somatic copy-number alteration across human cancers. Nature 463
Mitsudomi, T. et al.
Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epider-
mal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11
Hodi, F.S. et al.
Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363
Heidorn, S.J. et al.
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140
Verhaak, R.G. et al.
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in
PDGFRA, IDH1, EGFR and NF1. Cancer Cell 17
Sternberg, C.N. et al.
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin.
Poulikakos, P.I. et al.
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464
Ward, P.S. et al.
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting a-keto-
glutarate to 2-hydroxyglutarate. Cancer Cell 17
Hatzivassiliou, G. et al.
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464
Rajkumar, S.V. et al.
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for
newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11
Andriole, G.L. et al.
Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 362
Bonner, J.A. et al.
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 ran-
domised trial, and relation between cetuximab-induced rash and survival.
Lancet Oncol. 11
Flaherty, K.T. et al.
Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363
Atkin, W.S. et al.
Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial.
Davis, M.E. et al.
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464
Maemondo, M. et al.
Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive,
oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11
Dalgliesh, G.L. et al.
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463
Ding, L. et al.
Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464
Sharma, S.V. et al.
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141
Morin, R.D. et al.
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat.
Gupta, R.A. et al.
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464
Douillard, J.-Y. et al.
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non–small-cell lung cancer: data
from the randomized phase III INTEREST trial. J. Clin. Oncol. 28
Pece, S. et al.
Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140
Wacholder, S. et al.
Performance of common genetic variants in breast-cancer risk models. N. Engl. J. Med. 362
Roth, A.D. et al.
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28
Yao, J.C. et al.
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemo-
therapy: a phase II trial. J. Clin. Oncol. 28
Park, E.J. et al.
Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140
Folprecht, G. et al.
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with
cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 11
volume 17 | number 3 | march 2011 NAture medIcINe
FEDERACIÓN ESPIRITISTA KARDECIANA DA LA FLORIDA, INC. (FEKDFLA) P.O. BOX 526822 – Miami, Florida 33151, U.S.A. “ESTATUTOS” DE LA FEDERACIÓN ESPIRITISTA KARDECIANA DE LA Capítulo I Del Nombre, Constitución y Jurisdicción Art. 1 – La agrupación (no lucrativa) que por estos Estatutos se regula, se donomina KARDECIAN SPIRITIST FEDERATION OF FLORIDA INCORPORATED (Federación E
Rakel & Bope_Section-14 10/29/03 12:55 PM Page 959 TREATMENT OF TOURETTE’S 5. Use of stimulants . Because stimulants can maketics worse, it is often assumed that stimulants are con- SYNDROME traindicated in the treatment of TS. In reality, the ticsare often mild and easy to treat, and it is the co-morbidADHD that causes the greatest disability. Failureto address and treat the ADHD